If FCR could be the treatment of option, caution need to be taken in people with NOTCH1 mutations, in whom rituximab seems to get minor included benefit.fifty nine Other genomic subgroups, such as individuals with BIRC3 mutations seem to derive minor take advantage of CIT,111,112 but these final results must https://paulg196ygn3.eedblog.com/profile